Recrutamento encerrado
FASE
Número Europeu 2018-003075-35
D7980C00001
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors
Detalhes
Destaques